Better Care for PFAS Patients Act of 2026

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 6977 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 6977 To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES January 8, 2026 Ms. Dexter (for herself and Mr. Lawler) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Better Care for PFAS Patients Act of 2026''. SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, RECOMMENDATIONS, AND GUIDANCE. (a) Periodic Assessment and Recommendations.-- (1) Agreement.--The Director of the Agency for Toxic Substances and Disease Registry (in this section referred to as the ``Director'') shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (or another appropriate entity if the National Academies declines to enter into such agreement) under which the National Academies or the other appropriate entity agrees-- (A) to assess the health effects of per- and polyfluoroalkyl substances (in this section referred to as ``PFAS'') that can be measured in human tissues; (B) to formulate clinical recommendations on addressing such health effects; (C) not later than 2 years after the date of entry into such agreement, to complete the initial assessment under subparagraph (A) and formulate the initial recommendations under subparagraph (B); and